Showing 3551-3560 of 4877 results for "".
Beware of Your CPA's Advice on Asset Protection
https://practicaldermatology.com/topics/practice-management/beware-of-your-cpas-advice-on-asset-protection/21234/The advice you get may be inaccurate.A Definitive Guide to Recognizing and Treating “Maskne”
https://practicaldermatology.com/columns/clinical-focus-1/a-definitive-guide-to-recognizing-and-treating-maskne/23520/Practical Dermatology® magazine’s resident acne columnist offers step-by-step guidance.Comorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.Non-genital Warts: A Review of Current Treatments
https://practicaldermatology.com/topics/general-topics/non-genital-warts-a-review-of-current-treatments/21884/When determining which treatment modality to choose for non-genital warts, there are several factors to consider, including the convenience of the treatment, patient discomfort, location of warts, and potential side effects.Valeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicOn the Leading Edge, Not the Bleeding Edge: Joe Niamtu, DMD
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/on-the-leading-edge-not-the-bleeding-edge-joe-niamtu-dmd/18606/Innovator, influencer, and podium perennial Joe Niatmu, III, DMD has built a successful surgical aesthetic practice by focusing on the basics, concentrating on his strengths, and avoiding passing fads. How does he stay passionate, spot the best new developments, and build a fulfilling practice? In tDr. Ross Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-ross-discusses-experience-with-gemini-laser/19470/“There are a lot of new technologies out there, but one of the tried-and-true technologies is KTP laser and the long-pulse YAG laser. And the Gemini fits the bill for both of those wavelengths. So in a sense the Gemini is a time-tested product. It has served us well at our clinic, both at the NavyAbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society anEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, and